Hilbert Healthcare
Levosulpiride (75mg) + Esomeprazole (40mg)
Esmocam-LS Capsule SR is a prescription medicine used to treat gastroesophageal reflux disease (acid reflux) by relieving symptoms such as heartburn, stomach pain, or irritation.
Capsule SR
Esmocam-LS Capsule SR is a prescription medicine used in the treatment of gastroesophageal reflux disease (acid reflux). It works by relieving the symptoms such as heartburn, stomach pain, or irritation. It also neutralizes the acid production in the stomach to prevent discomfort.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Esmocam-LS Capsule SR is to be taken empty stomach.
Esmocam-LS Capsule SR is a combination of two medicines: Levosulpiride and Esomeprazole.
Do not consume alcohol while taking Esmocam-LS Capsule SR as it can increase the risk of stomach damage. Long-term use may cause weak or broken bones. Take adequate intake of dietary calcium and vitamin D or their supplements. Do not take Esmocam-LS Capsule SR for longer than prescribed.
Keep this medicine in its original container or pack it came in, tightly closed. Store it according to the instructions on the label or packaging. Do not dispose of this medication down the drain; it can be harmful to the environment. Make sure it is not accessible by pets, children, or other people.
Take Esmocam-LS Capsule SR exactly as directed by your healthcare provider. It's best to take one capsule daily on an empty stomach.
The use of Esmocam-LS Capsule SR should be avoided in patients with known allergies to any component or excipients of this medicine.
Yes, some patients may experience dizziness (feeling faint, weak, unsteady, or lightheaded) after taking Esmocam-LS Capsule SR. If you feel dizzy, it's best to rest and resume once you are feeling better.
Several studies in adults suggest that treatment with Esmocam-LS Capsule SR may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk was higher in patients who received high doses, defined as multiple daily doses over time, and those undergoing long-term therapy (1 year or longer).